Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Breaks Above Fifty Day Moving Average – What’s Next?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)’s stock price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.38 and traded as high as $4.63. Galmed Pharmaceuticals shares last traded at $4.59, with a volume of 302,067 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Galmed Pharmaceuticals Stock Down 0.9%

The stock’s 50 day moving average is $4.39 and its 200-day moving average is $4.69. The company has a market cap of $4.78 million, a PE ratio of -0.30 and a beta of 0.67.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) EPS for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is an Israeli clinical-stage biopharmaceutical company focused on developing treatments for liver and metabolic diseases. The company’s research has centered on nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease associated with fat accumulation and inflammation.

Galmed’s lead product candidate has been aramchol, an orally administered synthetic conjugate of a fatty acid and bile acid.